Age-related hearing loss
Conditions
Interventions
Experimental Group:Oral administration of Coenzyme Q10 tablets, 3 tablets each time, 3 times daily (administered orally half an hour after meals, total daily dose: 90 mg).
Control Group:Oral administration of a placebo identical in appearance, size, color, and taste to the experimental group drug, with the same dosage and administration as the experimental group.
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age between 50 and 80 years; 2. Meeting the diagnostic criteria for age-related hearing loss: bilateral, symmetric, and progressive sensorineural hearing loss; 3. Not using hearing aids and having not undergone cochlear implantation; 4. Voluntary participation in this project (with signed informed consent).
Exclusion criteria
Exclusion criteria: 1. Hearing loss attributable to other identifiable etiologies (e.g., otitis media, Ménière's disease, history of ear surgery, sudden sensorineural hearing loss, etc.); 2. Asymmetric sensorineural hearing loss (defined as an interaural difference of >=20 dB at two consecutive frequencies or >=15 dB at any two frequencies between 2 kHz and 8 kHz); 3. Current or planned use of other medications known to be ototoxic or potentially affecting hearing (e.g., aminoglycosides, loop diuretics, high-dose aspirin, etc.); 4. Known allergy or hypersensitivity to Coenzyme Q10 or any excipients; 5. Presence of severe or unstable cardiac, hepatic, or renal dysfunction (e.g., NYHA Class III-IV heart failure, ALT/AST > 2 times the upper limit of normal, eGFR < 60 mL/min/1.73m²).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pure tone hearing threshold; | — |
Secondary
| Measure | Time frame |
|---|---|
| Word recognition score;Tinnitus assessment;Hearing Handicap Inventory for the Elderly-Screening; | — |
Countries
China
Contacts
Public ContactWang Qiuju
Chinese PLA General Hospital
Outcome results
None listed